Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCQB: ADXS and ADXSD), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced updated preliminary data from a dose escalation Phase 1 study evaluating the safety and efficacy of ADXS-cHER2 in the treatment of dogs with osteosarcoma that overexpress human epidural growth factor receptor-2, or HER2.
Help employers find you! Check out all the jobs and post your resume.
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCQB: ADXS and ADXSD), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced updated preliminary data from a dose escalation Phase 1 study evaluating the safety and efficacy of ADXS-cHER2 in the treatment of dogs with osteosarcoma that overexpress human epidural growth factor receptor-2, or HER2.
Help employers find you! Check out all the jobs and post your resume.
